CONMED (NASDAQ:CNMD) had its price target upped by Leerink Swann from $60.00 to $64.00 in a research
note issued to investors on Tuesday. The firm currently has an outperform rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Northland Capital Partners initiated coverage on shares of CONMED in a research note on Friday. They set an outperform rating and a $65.00 price target on the stock. Analysts at Northland Securities initiated coverage on shares of CONMED in a research note on Thursday, May 14th. They set an outperform rating and a $65.00 price target on the stock. Analysts at Zacksupgraded shares of CONMED from a sell rating to a hold rating in a research note on Tuesday, May 5th. Finally, analysts at Deutsche Bank initiated coverage on shares of CONMED in a research note on Monday, May 4th. They set a buy rating and a $63.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $57.78.
